• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Bausch Health Companies Inc.

    3/16/21 5:00:21 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BHC alert in real time by email
    SC 13D/A 1 bhcsc13da03162021.htm
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*

    Bausch Health Companies Inc.
    (Name of Issuer)

    Common Stock, no par value
    (Title of Class of Securities)

    071734107
    (CUSIP Number)

    Andrew Langham
    Icahn Capital LP
    16690 Collins Avenue
    Sunny Isles Beach, FL 33160
    (305) 422-4100

    (Name, Address and Telephone Number of Person Authorized to
    Receive Notices and Communications)

    March 16, 2021
    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Section 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box / /.

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d‑7 for other parties to whom copies are to be sent.

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    SCHEDULE 13D

    CUSIP No. 071734107


    1. NAME OF REPORTING PERSON
    Icahn Partners Master Fund LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) / /
    (b) / /

    3 SEC USE ONLY

    4 SOURCE OF FUNDS
    WC

    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)/ /

    6 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

    7 SOLE VOTING POWER
    14,169,189

    8 SHARED VOTING POWER
    0

    9 SOLE DISPOSITIVE POWER
     14,169,189

    10 SHARED DISPOSITIVE POWER
    0

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     14,169,189

    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES/ /

    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    3.98%

    14 TYPE OF REPORTING PERSON
    PN

    SCHEDULE 13D

    CUSIP No. 071734107


    1. NAME OF REPORTING PERSON
    Icahn Offshore LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) / /
    (b) / /

    3 SEC USE ONLY

    4 SOURCE OF FUNDS
    OO

    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)/ /

    6 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

    7 SOLE VOTING POWER
    0

    8 SHARED VOTING POWER
     14,169,189

    9 SOLE DISPOSITIVE POWER
    0

    10 SHARED DISPOSITIVE POWER
     14,169,189

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     14,169,189

    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES/ /

    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    3.98%

    14 TYPE OF REPORTING PERSON
    PN

    SCHEDULE 13D

    CUSIP No. 071734107


    1. NAME OF REPORTING PERSON
    Icahn Partners LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) / /
    (b) / /

    3 SEC USE ONLY

    4 SOURCE OF FUNDS
    WC

    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)/ /

    6 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

    7 SOLE VOTING POWER
     19,939,963

    8 SHARED VOTING POWER
    0

    9 SOLE DISPOSITIVE POWER
     19,939,963

    10 SHARED DISPOSITIVE POWER
    0

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     19,939,963

    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES/ /

    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
      5.61%

    14 TYPE OF REPORTING PERSON
    PN

    SCHEDULE 13D

    CUSIP No. 071734107


    1. NAME OF REPORTING PERSON
    Icahn Onshore LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) / /
    (b) / /

    3 SEC USE ONLY

    4 SOURCE OF FUNDS
    OO

    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)/ /

    6 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

    7 SOLE VOTING POWER
    0

    8 SHARED VOTING POWER
     19,939,963

    9 SOLE DISPOSITIVE POWER
    0

    10 SHARED DISPOSITIVE POWER
     19,939,963

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     19,939,963

    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES/ /

    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     5.61%

    14 TYPE OF REPORTING PERSON
    PN

    SCHEDULE 13D

    CUSIP No. 071734107


    1. NAME OF REPORTING PERSON
    Icahn Capital LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) / /
    (b) / /

    3 SEC USE ONLY

    4 SOURCE OF FUNDS
    OO

    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)/ /

    6 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

    7 SOLE VOTING POWER
    0

    8 SHARED VOTING POWER
     34,109,152

    9 SOLE DISPOSITIVE POWER
    0

    10 SHARED DISPOSITIVE POWER
     34,109,152

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     34,109,152

    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES/ /

    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    9.59%

    14 TYPE OF REPORTING PERSON
    PN


    SCHEDULE 13D

    CUSIP No. 071734107


    1. NAME OF REPORTING PERSON
    IPH GP LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) / /
    (b) / /

    3 SEC USE ONLY

    4 SOURCE OF FUNDS
    OO

    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)/ /

    6 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

    7 SOLE VOTING POWER
    0

    8 SHARED VOTING POWER
     34,109,152

    9 SOLE DISPOSITIVE POWER
    0

    10 SHARED DISPOSITIVE POWER
     34,109,152

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     34,109,152

    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES/ /

    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    9.59%

    14 TYPE OF REPORTING PERSON
    OO

    SCHEDULE 13D

    CUSIP No. 071734107


    1. NAME OF REPORTING PERSON
    Icahn Enterprises Holdings L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) / /
    (b) / /

    3 SEC USE ONLY

    4 SOURCE OF FUNDS
    OO

    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)/ /

    6 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

    7 SOLE VOTING POWER
    0

    8 SHARED VOTING POWER
     34,109,152

    9 SOLE DISPOSITIVE POWER
    0

    10 SHARED DISPOSITIVE POWER
     34,109,152

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     34,109,152

    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES/ /

    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    9.59%

    14 TYPE OF REPORTING PERSON
    PN

    SCHEDULE 13D

    CUSIP No. 071734107


    1. NAME OF REPORTING PERSON
    Icahn Enterprises G.P. Inc.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) / /
    (b) / /

    3 SEC USE ONLY

    4 SOURCE OF FUNDS
    OO

    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)/ /

    6 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

    7 SOLE VOTING POWER
    0

    8 SHARED VOTING POWER
     34,109,152

    9 SOLE DISPOSITIVE POWER
    0

    10 SHARED DISPOSITIVE POWER
     34,109,152

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     34,109,152

    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES/ /

    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    9.59%

    14 TYPE OF REPORTING PERSON
    CO

    SCHEDULE 13D

    CUSIP No. 071734107


    1. NAME OF REPORTING PERSON
    Beckton Corp.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) / /
    (b) / /

    3 SEC USE ONLY

    4 SOURCE OF FUNDS
    OO

    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)/ /

    6 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

    7 SOLE VOTING POWER
    0

    8 SHARED VOTING POWER
     34,109,152

    9 SOLE DISPOSITIVE POWER
    0

    10 SHARED DISPOSITIVE POWER
     34,109,152

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     34,109,152

    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES/ /

    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    9.59%

    14 TYPE OF REPORTING PERSON
    CO

    SCHEDULE 13D

    CUSIP No. 071734107


    1 NAME OF REPORTING PERSON
    Carl C. Icahn

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) / /
    (b) / /

    3 SEC USE ONLY

    4 SOURCE OF FUNDS
    OO

    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)/ /

    6 CITIZENSHIP OR PLACE OF ORGANIZATION
    United States of America

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

    7 SOLE VOTING POWER
    0

    8 SHARED VOTING POWER
    34,109,152

    9 SOLE DISPOSITIVE POWER
    0

    10 SHARED DISPOSITIVE POWER
    34,109,152

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    34,109,152

    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES/ /

    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    9.59%

    14 TYPE OF REPORTING PERSON
    IN

    SCHEDULE 13D

    Item 1. Security and Issuer

    This statement constitutes Amendment No. 3 to the Schedule 13D relating to the shares of Common Stock, no par value (“Shares”), issued by Bausch Health Companies Inc. (the “Issuer”), and hereby amends the Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on February 11, 2021 (as amended, the “Schedule 13D”), as amended by Amendment No. 1 to the Schedule 13D filed with the SEC on February 24, 2021 and Amendment No. 2 to the Schedule 13D filed with the SEC on March 11, 2021, to furnish the additional information set forth herein. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.


    Item 3. Source and Amount of Funds or Other Consideration

    Item 3 of the Schedule 13D is hereby amended by replacing it in its entirety with the following:

     The Reporting Persons may be deemed to be the beneficial owner of, in the aggregate, 34,109,152 Shares, which were purchased by the Reporting Persons for an aggregate purchase price of approximately $422.3 million.

    The source of funding for the Shares (including Shares underlying forward contracts) held by the Reporting Persons was the general working capital of the respective purchasers. The Shares held by the Reporting Persons are held in margin accounts together with other securities. Such margin accounts may from time to time have debit balances. Part of the purchase price of such Shares was obtained through margin borrowing.


    Item 5. Interest in Securities of the Issuer

    Items 5(a) and (b) of the Schedule 13D are hereby amended by replacing them in their entirety with the following:

    (a) The Reporting Persons may be deemed to beneficially own, in the aggregate, 34,109,152 Shares, representing approximately 9.59% of the Issuer's outstanding Shares (based on the 355,619,826 Shares outstanding as of February 18, 2021, as disclosed by the Issuer in the Issuer’s Form 10-K for the fiscal year ended December 31, 2020).

    (b) Icahn Master has sole voting power and sole dispositive power with regard to 14,169,189 Shares. Each of Icahn Offshore, Icahn Capital, IPH, Icahn Enterprises Holdings, Icahn Enterprises GP, Beckton and Mr. Icahn has shared voting power and shared dispositive power with regard to such Shares. Icahn Partners has sole voting power and sole dispositive power with regard to 19,939,963 Shares. Each of Icahn Onshore, Icahn Capital, IPH, Icahn Enterprises Holdings, Icahn Enterprises GP, Beckton and Mr. Icahn has shared voting power and shared dispositive power with regard to such Shares.

    Each of Icahn Offshore, Icahn Capital, IPH, Icahn Enterprises Holdings, Icahn Enterprises GP, Beckton and Mr. Icahn, by virtue of their relationships to Icahn Master (as disclosed in Item 2), may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended, the “Act”) the Shares which Icahn Master directly beneficially owns. Each of Icahn Offshore, Icahn Capital, IPH, Icahn Enterprises Holdings, Icahn Enterprises GP, Beckton and Mr. Icahn disclaims beneficial ownership of such Shares for all other purposes. Each of Icahn Onshore, Icahn Capital, IPH, Icahn Enterprises Holdings, Icahn Enterprises GP, Beckton and Mr. Icahn, by virtue of their relationships to Icahn Partners (as disclosed in Item 2), may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Act) the Shares which Icahn Partners directly beneficially owns. Each of Icahn Onshore, Icahn Capital, IPH, Icahn Enterprises Holdings, Icahn Enterprises GP, Beckton and Mr. Icahn disclaims beneficial ownership of such Shares for all other purposes.

    (c) The following table sets forth all transactions with respect to Shares effected since the Reporting Persons filed Amendment No. 2 to the Schedule 13D on March 11, 2021. Except as otherwise noted below, all such transactions were purchases of Shares effected in the open market, and the table includes commissions paid in per share prices.


    Name of Reporting Person
    Date of Transaction
    Amount of Securities
    Price Per Share ($)
     
    Icahn Partners LP
    03/16/2021
       16,997,041   (1)
     $27.96  (2)
    Icahn Partners Master Fund LP
    03/16/2021
    12,078,964  (1)
    $27.96  (2)

    1.
    Represents Shares acquired pursuant to a forward contract. These forward contracts were set to expire on December 23, 2022. On March 16, 2021, the Reporting Persons exercised such forward contracts to acquire an aggregate of 29,076,005 Shares at an exercise price of $17.00 per Share, which represents all forward contracts held by the Reporting Persons as of the date of this filing, including the forward contracts to which this footnote is referenced.

    2.
    Represents a forward price of $17.00 per Share, plus the amount per Share the Reporting Person paid the counterparty to the forward contract upon entering into such forward contract. The forward price is subject to adjustment to account for any dividends or other distributions declared by the Issuer. In addition, the Reporting Person paid a financing charge to the counterparty to such forward contract.

    Item 6. Contracts, Arrangements, Understandings or Relationship with Respect to Securities of the Issuer

    Item 6 of the Schedule 13D is hereby amended to add the following:

    Forward Contracts

    The Reporting Persons entered into forward contracts providing for the purchase by such Reporting Persons of an aggregate of 29,076,005 Shares at a forward price of $17.00 per share, for an aggregate forward price of $494.3 million, plus a financing charge. The forward price is subject to adjustment to account for any dividends or other distributions declared by the Issuer. In addition, the Reporting Persons paid the counterparty to such forward contracts an aggregate amount of approximately $318.6 million upon entering into such forward contracts. The forward contracts would have expired on December 23, 2022.
    The forward contracts provided for physical settlement, with the Reporting Person retaining the right to elect cash settlement. The forward contracts did not give any Reporting Persons direct or indirect voting, investment or dispositive control over the Shares to which such contracts related.
    On March 16, 2021, the Reporting Persons exercised all such forward contracts and thereby acquired 29,076,005 Shares, in the aggregate.





    SIGNATURE

    After reasonable inquiry and to the best of each of the undersigned knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: March 16, 2021

    ICAHN PARTNERS MASTER FUND LP
    ICAHN OFFSHORE LP
    ICAHN PARTNERS LP
    ICAHN ONSHORE LP
    BECKTON CORP.

    By: /s/ Irene March
    Name: Irene March
    Title: Chief Compliance Officer


    ICAHN CAPITAL LP
    By: IPH GP LLC, its general partner
    By: Icahn Enterprises Holdings L.P., its sole member
    By: Icahn Enterprises G.P. Inc., its general partner
    IPH GP LLC
    By: Icahn Enterprises Holdings L.P., its sole member
    By: Icahn Enterprises G.P. Inc., its general partner
    ICAHN ENTERPRISES HOLDINGS L.P.
    By: Icahn Enterprises G.P. Inc., its general partner
    ICAHN ENTERPRISES G.P. INC.

    By: /s/ SungHwan Cho
    Name: SungHwan Cho
    Title: Chief Financial Officer



    /s/ Carl C. Icahn 
    CARL C. ICAHN

    [Signature Page of Schedule 13D Amendment No. 3  – Bausch Health Companies Inc.]


    Get the next $BHC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BHC

    DatePrice TargetRatingAnalyst
    8/2/2024$9.00 → $3.00Neutral → Underweight
    Piper Sandler
    7/10/2024$8.00Mkt Perform
    Raymond James
    9/20/2023$9.00 → $16.00Hold → Buy
    Jefferies
    6/16/2023Outperform → Market Perform
    TD Cowen
    7/29/2022Buy → Hold
    Truist
    7/29/2022$12.00 → $5.00Outperform → Sector Perform
    RBC Capital Mkts
    7/28/2022Overweight → Neutral
    JP Morgan
    6/13/2022$12.00Overweight
    JP Morgan
    More analyst ratings

    $BHC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program

      LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for Medicare and Medicaid Services (CMS) has selected XIFAXAN® (rifaximin) 550 mg tablets as one of the medicines for the second round of negotiation as part of the Inflation Reduction Act with an initial price applicability in 2027 of the Drug Price Negotiation program.We look forward to engaging in open and transparent conversations with CMS, where we will share information on the value that XIFAXAN® delivers for the healthcare system in addition to sharing recommendations from The American Assoc

      1/17/25 9:25:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb

      LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO):"As previously disclosed, the Company believes that completing the full separation of its subsidiary, Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb"), makes strategic sense. The Bausch Health Board of Directors authorized management and management of its subsidiary, Bausch + Lomb, to explore a potential sale, which is

      12/12/24 7:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day

      LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation (USPF), the International Foundation for Gastrointestinal Disorders (IFFGD), and the American Chronic Pain Association (ACPA) have united to recognize today, Thursday, December 5, as the second annual Opioid-Induced Constipation (OIC) Awareness Day. This important day is dedicated to bringing awareness to a commonly-overlooked side effect of opioids. By raising awareness and fostering open conversations, OIC Awareness Day seeks to reduce the stigma surrounding this condition and offer support t

      12/5/24 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHC
    Financials

    Live finance-specific insights

    See more
    • Bausch Health Announces Third Quarter 2024 Results

      Sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1Third quarter consolidated revenues of $2.51 billion, up 12% on a Reported basis and 9% on an Organic (non-GAAP)1 basis, with growth in all segmentsConsolidated GAAP Net Loss Attributable to Bausch Health Companies Inc. of $85 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $909 million, up 10%Raising full-year 2024 guidance LAVAL, QC / ACCESSWIRE / October 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third quarter 2024 financial results and other key updates fro

      10/30/24 4:05:00 PM ET
      $BHC
      $NHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Hospital/Nursing Management
    • Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024

      LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2024 financial results after market close on Wednesday, October 30, 2024. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:Wednesday, October 30, 2024Time:5:00 p.m. U.S. ESTWebcast:https://ir.bauschhealth.com/events-and-presentationsA replay of the conference call will be available on the investor relations website.To participate in t

      10/9/24 4:05:00 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health Announces Second Quarter 2024 Results

      Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP)1 basisConsolidated GAAP Net Income Attributable to Bausch Health Companies Inc. of $10 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $798 million, up 10%Raising consolidated full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidanceLAVAL, QC / ACCESSWIRE / August 1, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second quarter 2024 financial results and other key updates from the quarter."We continued our momentum in the second quarter, delivering our fifth

      7/31/24 12:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHC
    SEC Filings

    See more
    • Bausch Health Companies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Bausch Health Companies Inc. (0000885590) (Filer)

      4/30/25 4:11:13 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Bausch Health Companies Inc.

      DEFA14A - Bausch Health Companies Inc. (0000885590) (Filer)

      4/22/25 7:00:33 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form CERT filed by Bausch Health Companies Inc.

      CERT - Bausch Health Companies Inc. (0000885590) (Filer)

      4/17/25 9:29:12 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Bausch Health Companies Inc.

      SC 13G - Bausch Health Companies Inc. (0000885590) (Subject)

      8/30/24 6:12:52 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Bausch Health Companies Inc.

      SC 13D/A - Bausch Health Companies Inc. (0000885590) (Subject)

      8/19/24 5:48:41 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Bausch Health Companies Inc. (Amendment)

      SC 13G/A - Bausch Health Companies Inc. (0000885590) (Subject)

      2/13/24 4:30:26 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Wechsler Amy B was granted 1,062 shares, increasing direct ownership by 0.51% to 209,008 units (SEC Form 4)

      4 - Bausch Health Companies Inc. (0000885590) (Issuer)

      4/1/25 4:36:45 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Icahn Brett was granted 5,119 shares, increasing direct ownership by 3% to 161,899 units (SEC Form 4)

      4 - Bausch Health Companies Inc. (0000885590) (Issuer)

      4/1/25 4:35:23 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Paulson John was granted 9,659 shares, increasing direct ownership by 4% to 277,708 units (SEC Form 4)

      4 - Bausch Health Companies Inc. (0000885590) (Issuer)

      4/1/25 4:34:05 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bausch Health downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Bausch Health from Neutral to Underweight and set a new price target of $3.00 from $9.00 previously

      8/2/24 7:25:50 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James initiated coverage on Bausch Health with a new price target

      Raymond James initiated coverage of Bausch Health with a rating of Mkt Perform and set a new price target of $8.00

      7/10/24 8:35:33 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health upgraded by Jefferies with a new price target

      Jefferies upgraded Bausch Health from Hold to Buy and set a new price target of $16.00 from $9.00 previously

      9/20/23 7:27:08 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHC
    Leadership Updates

    Live Leadership Updates

    See more
    • Bausch Health Appoints New Chief Medical Officer and Head of R&D

      LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. This strategic addition to our leadership team underscores our commitment to innovation, excellence, and enriching lives.Jonathan brings a wealth of experience and a proven track record of success both as a physician-scientist and a leader in the pharmaceutical industry. With over 20 years of expertise in clinical research and drug development, he has consistently demonstrated the ability to drive growth and foster innovation. Most recently, at Bristol-Meyers Squibb,

      12/2/24 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health Welcomes Two New Members to the Executive Leadership Team

      LAVAL, QC / ACCESSWIRE / July 19, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the appointment of two new members to its Executive Leadership Team (ELT).Jean-Jacques Charhon ("JJ") will join the Company as Chief Financial Officer on August 19, 2024. JJ has over 25 years of experience in financial leadership roles with public and private companies across healthcare, high tech and services, primarily at General Electric, Hewlett Packard, Novartis and Purdue Pharma. Upon JJ's arrival, John Barresi, the Company's Interim Chief Financial Officer, will resume his role as SVP, Controller.Aimee Lenar joined the Company on July 15, 2024 as Executive Vice President, US Pharm

      7/19/24 7:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day

      BRIDGEWATER, NJ / ACCESSWIRE / December 5, 2023 / Salix Pharmaceuticals, the gastroenterology division of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), The U.S. Pain Foundation (USPF), and The International Foundation for Gastrointestinal Disorders (IFFGD) today announced they are joining forces to declare Tuesday, Dec. 5, Opioid-Induced Constipation (OIC) Awareness Day. OIC Awareness Day aims to bring awareness to an often-overlooked side effect of opioids. This day will help patients suffering from OIC by breaking down the stigma and silence surrounding this condition."OIC Awareness Day will help bridge the gap between healthcare providers (HCPs), patients, and caregivers by providing

      12/5/23 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care